- GlobeNewswire•24 days ago
Cyclacel Presents Identification of Sensitive Target Indications and Synergistic Drug Combinations for Novel PLK1 Inhibitor CYC140
-Preclinical Data Presented at the AACR 2017 Meeting-. BERKELEY HEIGHTS, N.J., April 04, 2017-- Cyclacel Pharmaceuticals, Inc., today announced the presentation of preclinical data outlining the potential ...
- GlobeNewswire•26 days ago
Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Cancer by Engaging Anti-Metastatic Pathways
BERKELEY HEIGHTS, N.J., April 02, 2017-- Cyclacel Pharmaceuticals, Inc., today announced the presentation by independent investigators of preclinical data demonstrating therapeutic potential of CYC065, ...
- GlobeNewswire•last month
BERKELEY HEIGHTS, N.J., March 28, 2017-- Cyclacel Pharmaceuticals, Inc. a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer ...
CYCCP : Summary for Cyclacel Pharmaceuticals, Inc. - Yahoo Finance
Cyclacel Pharmaceuticals, Inc. (CYCCP)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Ask||6.68 x 100|
|Day's Range||6.44 - 6.44|
|52 Week Range||4.21 - 11.29|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.84|
|Dividend & Yield||0.60 (8.16%)|
|1y Target Est||N/A|